Aurinia Pharmaceuticals Inc (AUPH.OQ)
16 Mar 2018
Fri, Mar 16 2018
* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:
* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:
* Aurinia reports third quarter 2017 financial results and provides operational highlights
* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing
* Aurinia Pharmaceuticals Inc - plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease
- Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q4 2017 Results - Earnings Call Transcript
- Altum Is Launching Biotech Insider
- Chemokine Receptor Antagonists: ChemoCentryx Is An Aged Red Wine Ripe For Success
- Aurinia Pharmaceuticals: Will AURORA Light The Way To Voclosporin's Approval?
- Aurinia Pharmaceuticals: Potential Rewards Far Outweigh The Risks
- Aurinia Pharmaceuticals' Voclosporin: A Blockbuster Drug Hidden In Plain Sight?